CAS: 1402709-93-6
Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
---|---|---|---|---|
CCT241736 REF: AN-AG01ENWXCAS: 1402709-93-6 | 98% | 161,00 €~613,00 € | Jue 09 May 24 | |
CCT241736 REF: TM-T4428CAS: 1402709-93-6 | 99.88% | 59,00 €~482,00 € | Jue 16 May 24 | |
CCT241736 REF: 3D-CGC70993CAS: 1402709-93-6 | Min. 95% | A consultar | Jue 20 Jun 24 |
Ref: AN-AG01ENWX
50mg | 161,00 € | |
100mg | 272,00 € | |
250mg | 613,00 € |
Entrega estimada en Estados Unidos, el Jueves 9 de Mayo de 2024
CCT241736
CAS:1402709-93-6
CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant …
Fórmula:
C22H23Cl2N7
Pureza:
99.88%
Forma y color:
Solid
Peso molecular:
456.37
Ref: TM-T4428
5mg | 59,00 € | |
10mg | 96,00 € | |
25mg | 167,00 € | |
50mg | 323,00 € | |
100mg | 482,00 € | |
1ml*10 (DMSO) | 66,00 € |
Entrega estimada en Estados Unidos, el Jueves 16 de Mayo de 2024
CCT241736
CAS:1402709-93-6
CCT241736 is an effective dose of a clinical drug that belongs to the class of …
Fórmula:
C22H23Cl2N7
Pureza:
Min. 95%
Peso molecular:
456.37 g/mol
Ref: 3D-CGC70993
5mg | A consultar | |
10mg | A consultar | |
25mg | A consultar | |
50mg | A consultar | |
100mg | A consultar |
Entrega estimada en Estados Unidos, el Jueves 20 de Junio de 2024